Activated T cells from human peripheral blood that were edited to lack the CD96 gene exhibited enhanced killing of K562 CML and MOLM14 AML tumor cells expressing the CD96 ligand CD155 compared with mock-edited control cells. Here, CD96 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.